First-in-Human cell therapy tested for rare muscle disease
NCT ID NCT05451212
Summary
This early-stage study tested the safety of a new cell therapy called MuSK-CAART in seven people with a rare autoimmune disease that causes severe muscle weakness. Researchers gave different doses, sometimes with other medications, to see how the body handled the treatment. The goal was to find a safe dose for future studies, with the hope this therapy could lead to long-term disease remission.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MUSK MYASTHENIA GRAVIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Houston Methodist Hospital
Houston, Texas, 77030, United States
-
Oregon Health & Science University (OHSU)
Portland, Oregon, 97239, United States
-
UC Davis, Department of Neurology
Sacramento, California, 95817, United States
-
UC Irvine, Department of Neurology
Orange, California, 92868, United States
-
University of Kansas Medical Center
Kansas City, Kansas, 66160, United States
Conditions
Explore the condition pages connected to this study.